Tech Company Financing Transactions

Pliant Therapeutics Funding Round

Third Rock Ventures and private investors participated in a $45 million Series A funding round for Pliant Therapeutics. The financing round was recorded on 2/19/2016.

Transaction Overview

Announced On
2/19/2016
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors

Third Rock Ventures (Neil Exter)

Proceeds Purpose
Pliant's product engine has the potential to address the needs of many patients by targeting fibrosis in a variety of organs and conditions, including the lungs (IPF), liver (NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma), heart (cardiac fibrosis) and the gastrointestinal tract (Crohn's disease).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
260 Littlefield Ave.
San Francisco, CA 94080
USA
Email Address
Overview
Pliant Therapeutics (Nasdaq: PLRX) is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Profile
Pliant Therapeutics LinkedIn Company Profile
Social Media
Pliant Therapeutics Company Twitter Account
Company News
Pliant Therapeutics News
Facebook
Pliant Therapeutics on Facebook
YouTube
Pliant Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bernard Coulie
  Bernard Coulie LinkedIn Profile  Bernard Coulie Twitter Account  Bernard Coulie News  Bernard Coulie on Facebook
Chief Financial Officer
Keith Cummings
  Keith Cummings LinkedIn Profile  Keith Cummings Twitter Account  Keith Cummings News  Keith Cummings on Facebook
Chief Medical Officer
Eric Lefebvre
  Eric Lefebvre LinkedIn Profile  Eric Lefebvre Twitter Account  Eric Lefebvre News  Eric Lefebvre on Facebook
Vice President
Katerina Leftheris
  Katerina Leftheris LinkedIn Profile  Katerina Leftheris Twitter Account  Katerina Leftheris News  Katerina Leftheris on Facebook
Vice President
Scott Turner
  Scott Turner LinkedIn Profile  Scott Turner Twitter Account  Scott Turner News  Scott Turner on Facebook
VP - Bus. Development
Hans Hull
  Hans Hull LinkedIn Profile  Hans Hull Twitter Account  Hans Hull News  Hans Hull on Facebook
VP - Bus. Development
Eve-Irene Lepist
  Eve-Irene Lepist LinkedIn Profile  Eve-Irene Lepist Twitter Account  Eve-Irene Lepist News  Eve-Irene Lepist on Facebook
VP - Human Resources
Barbara Howes
  Barbara Howes LinkedIn Profile  Barbara Howes Twitter Account  Barbara Howes News  Barbara Howes on Facebook
VP - Operations
Marzena Jurek
  Marzena Jurek LinkedIn Profile  Marzena Jurek Twitter Account  Marzena Jurek News  Marzena Jurek on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/19/2016: Armune BioScience venture capital transaction
Next: 2/19/2016: eFFECTOR Therapeutics venture capital transaction

 

Share this article

 


About Database of VC Transactions

Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary